Roche Holding AG ADR RHHBY
-
2 Pharmaceutical Companies Trading Below Net Cash
By Markus Aarnio : Since my last article in February about Myrexis ( MYRX ) we have seen a small pop in the share price and a subsequent drop as well. The pop was due to a press release given on February 15th stating that company's Board of Directors has retained Stifel Nicolaus Weisel, an ...
-
Galena Biopharma With Near Term ASCO Catalyst
By The Swiss Trader : Galena ( GALE ) is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics. The company is pursuing the development of novel cancer therapeutics using peptide-based
-
Investment Choices For Melanoma Awareness Month
By Amy Baldwin : Affecting more than 65,000 new patients and claiming about 11,000 lives annually, melanoma treatment represents a huge unmet need. With the knowledge that sun exposure is responsible for the cause of about two-thirds of all melanoma cases, May has been dubbed " melanoma awareness
-
New Morningstar Analyst Report for Qiagen NV
… establish a greater footprint within molecular diagnostics. Given the stiff competition present from larger powerhouses like Roche RHHBY , Hologic HOLX, Gen-Probe GPRO, and others, Qiagen's competitive advantages in this market are less certain and prevent …
-
New Morningstar Analyst Report - Hospira, Inc.
… living organisms. Biosimilars coming off patent over the next decade for drugs such as Amgen's AMGN Epogen and Roche's RHHBY Rituxan create big opportunities for generic drug manufacturers. However, the very high development, manufacturing, and …
-
Lpath Back In Play
By Brian L. Wilson : It's time to start tracking Lpath ( LPTN.OB ) again. The San Diego-based pharmaceutical company is leading a new trend of lipid-based therapies and shares are once again on the rise as speculators begin to watch their drug portfolio and rumors of a takeover by pharmaceutical ...
-
Roche ( RHHBY .PK) has won the right for its crenezumab Alzheimer's drug to take part in a study that will assess whether it can be used as a preventative treatment. Crenezumab will be tested on an ...
Roche ( RHHBY .PK ) has won the right for its crenezumab Alzheimer's drug to take part in a study that will assess whether it can be used …
-
GlaxoSmithKline's 4.8% Yield Makes It Attractive With Or Without Human Genome Takeover
By Investment Underground : by Larry Gellar After failing to reach a buyout deal with Human Genome Sciences ( HGSI ) , GlaxoSmithKline ( GSK ) will now make a cash tender offer to the company's shareholders for $13 per share. Considering Human Genome Sciences' top ten shareholders own 78% of the ...
-
Yield, Value, Safety: Are They Still Available For Big Pharma? (Part 2)
… billion (mega cap, U.S.) Novartis A G ADR ( NVS ), $130 billion (mega cap, Switzerland) Roche Holdings LTD ADR ( RHHBY ), $120 billion (mega cap, Switzerland) Merck & Co ( MRK ), $116 billion (mega cap, U.S.) GlaxoSmithKline PLC ADR …
-
Bloomberg provides a survey of drugs for the central nervous system and dresses it up as an interview with Roche ( RHHBY .PK) CEO Severin Schwan. One advantage that Roche may have is its experience ...
Bloomberg provides a survey of drugs for the central nervous system and dresses it up as an interview with Roche ( RHHBY .PK ) CEO Severin Schwan. One advantage that Roche may have is its experience with treatments that are tailored to patients …